Effects of Bisphosphonates on the Growth of Entamoeba histolytica and Plasmodium Species in Vitro and in Vivo

Subhash Ghosh, Julian M W Chan, Christopher R. Lea, Gary A. Meints, Jared C. Lewis, Zev S. Tovian, Ryan M. Flessner, Timothy C. Loftus, Iris Bruchhaus, Howard Kendrick, Simon L. Croft, Robert G. Kemp, Seike Kobayashi, Tomoyoshi Nozaki, Eric Oldfield

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

The effects of a series of 102 bisphosphonates on the inhibition of growth of Entamoeba histolytica and Plasmodium falciparum in vitro have been determined, and selected compounds were further investigated for their in vivo activity. Forty-seven compounds tested were active (IC50 < 200 μM) versus E. histolytica growth in vitro. The most active compounds (IC 50 ∼ 4-9 μM) were nitrogen-containing bisphosphonates with relatively large aromatic side chains. Simple n-alkyl-1-hydroxy-1,1-bisphosphonates, known inhibitors of the enzyme farnesylpyrophosphate (FPP) synthase, were also active, with optimal activity being found with C9-C10 side chains. However, numerous other nitrogen-containing bisphosphonates known to be potent FPP synthase inhibitors, such as risedronate or pamidronate, had little or no activity. Several pyridine-derived bisphosphonates were quite active (IC50 ∼ 10-20 μM), and this activity was shown to correlate with the basicity of the aromatic group, with activity decreasing with increasing pKa values. The activities of all compounds were tested versus a human nasopharyngeal carcinoma (KB) cell line to enable an estimate of the therapeutic index (TI). Five bisphosphonates were selected and then screened for their ability to delay the development of amebic liver abscess formation in an E. histolytica infected hamster model. Two compounds were found to decrease liver abscess formation at 10 mg/kg ip with little or no effect on normal liver mass. With P. falciparum, 35 compounds had IC50 values <200 μM in an in vitro assay. The most active compounds were also simple n-alkyl-1-hydroxy-1,1-bisphosphonates, having IC50 values around 1 μM. Five compounds were again selected for in vivo investigation in a Plasmodium berghei ANKA BALB/c mouse suppressive test. The most active compound, a C9 n-alkyl side chain containing bisphosphonate, caused an 80% reduction in parasitemia with no overt toxicity. Taken together, these results show that bisphosphonates appear to be useful lead compounds for the development of novel antiamebic and antimalarial drugs.

Original languageEnglish
Pages (from-to)175-187
Number of pages13
JournalJournal of Medicinal Chemistry
Volume47
Issue number1
DOIs
Publication statusPublished - 2004 Jan 1

Fingerprint

Entamoeba histolytica
Plasmodium
Diphosphonates
Growth
Inhibitory Concentration 50
Liver
pamidronate
Plasmodium falciparum
Nitrogen
Amoebic Liver Abscess
Lead compounds
KB Cells
In Vitro Techniques
Plasmodium berghei
Liver Abscess
Parasitemia
Antimalarials
Enzyme Inhibitors
Alkalinity
Cricetinae

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Ghosh, S., Chan, J. M. W., Lea, C. R., Meints, G. A., Lewis, J. C., Tovian, Z. S., ... Oldfield, E. (2004). Effects of Bisphosphonates on the Growth of Entamoeba histolytica and Plasmodium Species in Vitro and in Vivo. Journal of Medicinal Chemistry, 47(1), 175-187. https://doi.org/10.1021/jm030084x

Effects of Bisphosphonates on the Growth of Entamoeba histolytica and Plasmodium Species in Vitro and in Vivo. / Ghosh, Subhash; Chan, Julian M W; Lea, Christopher R.; Meints, Gary A.; Lewis, Jared C.; Tovian, Zev S.; Flessner, Ryan M.; Loftus, Timothy C.; Bruchhaus, Iris; Kendrick, Howard; Croft, Simon L.; Kemp, Robert G.; Kobayashi, Seike; Nozaki, Tomoyoshi; Oldfield, Eric.

In: Journal of Medicinal Chemistry, Vol. 47, No. 1, 01.01.2004, p. 175-187.

Research output: Contribution to journalArticle

Ghosh, S, Chan, JMW, Lea, CR, Meints, GA, Lewis, JC, Tovian, ZS, Flessner, RM, Loftus, TC, Bruchhaus, I, Kendrick, H, Croft, SL, Kemp, RG, Kobayashi, S, Nozaki, T & Oldfield, E 2004, 'Effects of Bisphosphonates on the Growth of Entamoeba histolytica and Plasmodium Species in Vitro and in Vivo', Journal of Medicinal Chemistry, vol. 47, no. 1, pp. 175-187. https://doi.org/10.1021/jm030084x
Ghosh, Subhash ; Chan, Julian M W ; Lea, Christopher R. ; Meints, Gary A. ; Lewis, Jared C. ; Tovian, Zev S. ; Flessner, Ryan M. ; Loftus, Timothy C. ; Bruchhaus, Iris ; Kendrick, Howard ; Croft, Simon L. ; Kemp, Robert G. ; Kobayashi, Seike ; Nozaki, Tomoyoshi ; Oldfield, Eric. / Effects of Bisphosphonates on the Growth of Entamoeba histolytica and Plasmodium Species in Vitro and in Vivo. In: Journal of Medicinal Chemistry. 2004 ; Vol. 47, No. 1. pp. 175-187.
@article{50f7cc505b8a44748f6e1e4f3548ad67,
title = "Effects of Bisphosphonates on the Growth of Entamoeba histolytica and Plasmodium Species in Vitro and in Vivo",
abstract = "The effects of a series of 102 bisphosphonates on the inhibition of growth of Entamoeba histolytica and Plasmodium falciparum in vitro have been determined, and selected compounds were further investigated for their in vivo activity. Forty-seven compounds tested were active (IC50 < 200 μM) versus E. histolytica growth in vitro. The most active compounds (IC 50 ∼ 4-9 μM) were nitrogen-containing bisphosphonates with relatively large aromatic side chains. Simple n-alkyl-1-hydroxy-1,1-bisphosphonates, known inhibitors of the enzyme farnesylpyrophosphate (FPP) synthase, were also active, with optimal activity being found with C9-C10 side chains. However, numerous other nitrogen-containing bisphosphonates known to be potent FPP synthase inhibitors, such as risedronate or pamidronate, had little or no activity. Several pyridine-derived bisphosphonates were quite active (IC50 ∼ 10-20 μM), and this activity was shown to correlate with the basicity of the aromatic group, with activity decreasing with increasing pKa values. The activities of all compounds were tested versus a human nasopharyngeal carcinoma (KB) cell line to enable an estimate of the therapeutic index (TI). Five bisphosphonates were selected and then screened for their ability to delay the development of amebic liver abscess formation in an E. histolytica infected hamster model. Two compounds were found to decrease liver abscess formation at 10 mg/kg ip with little or no effect on normal liver mass. With P. falciparum, 35 compounds had IC50 values <200 μM in an in vitro assay. The most active compounds were also simple n-alkyl-1-hydroxy-1,1-bisphosphonates, having IC50 values around 1 μM. Five compounds were again selected for in vivo investigation in a Plasmodium berghei ANKA BALB/c mouse suppressive test. The most active compound, a C9 n-alkyl side chain containing bisphosphonate, caused an 80{\%} reduction in parasitemia with no overt toxicity. Taken together, these results show that bisphosphonates appear to be useful lead compounds for the development of novel antiamebic and antimalarial drugs.",
author = "Subhash Ghosh and Chan, {Julian M W} and Lea, {Christopher R.} and Meints, {Gary A.} and Lewis, {Jared C.} and Tovian, {Zev S.} and Flessner, {Ryan M.} and Loftus, {Timothy C.} and Iris Bruchhaus and Howard Kendrick and Croft, {Simon L.} and Kemp, {Robert G.} and Seike Kobayashi and Tomoyoshi Nozaki and Eric Oldfield",
year = "2004",
month = "1",
day = "1",
doi = "10.1021/jm030084x",
language = "English",
volume = "47",
pages = "175--187",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Effects of Bisphosphonates on the Growth of Entamoeba histolytica and Plasmodium Species in Vitro and in Vivo

AU - Ghosh, Subhash

AU - Chan, Julian M W

AU - Lea, Christopher R.

AU - Meints, Gary A.

AU - Lewis, Jared C.

AU - Tovian, Zev S.

AU - Flessner, Ryan M.

AU - Loftus, Timothy C.

AU - Bruchhaus, Iris

AU - Kendrick, Howard

AU - Croft, Simon L.

AU - Kemp, Robert G.

AU - Kobayashi, Seike

AU - Nozaki, Tomoyoshi

AU - Oldfield, Eric

PY - 2004/1/1

Y1 - 2004/1/1

N2 - The effects of a series of 102 bisphosphonates on the inhibition of growth of Entamoeba histolytica and Plasmodium falciparum in vitro have been determined, and selected compounds were further investigated for their in vivo activity. Forty-seven compounds tested were active (IC50 < 200 μM) versus E. histolytica growth in vitro. The most active compounds (IC 50 ∼ 4-9 μM) were nitrogen-containing bisphosphonates with relatively large aromatic side chains. Simple n-alkyl-1-hydroxy-1,1-bisphosphonates, known inhibitors of the enzyme farnesylpyrophosphate (FPP) synthase, were also active, with optimal activity being found with C9-C10 side chains. However, numerous other nitrogen-containing bisphosphonates known to be potent FPP synthase inhibitors, such as risedronate or pamidronate, had little or no activity. Several pyridine-derived bisphosphonates were quite active (IC50 ∼ 10-20 μM), and this activity was shown to correlate with the basicity of the aromatic group, with activity decreasing with increasing pKa values. The activities of all compounds were tested versus a human nasopharyngeal carcinoma (KB) cell line to enable an estimate of the therapeutic index (TI). Five bisphosphonates were selected and then screened for their ability to delay the development of amebic liver abscess formation in an E. histolytica infected hamster model. Two compounds were found to decrease liver abscess formation at 10 mg/kg ip with little or no effect on normal liver mass. With P. falciparum, 35 compounds had IC50 values <200 μM in an in vitro assay. The most active compounds were also simple n-alkyl-1-hydroxy-1,1-bisphosphonates, having IC50 values around 1 μM. Five compounds were again selected for in vivo investigation in a Plasmodium berghei ANKA BALB/c mouse suppressive test. The most active compound, a C9 n-alkyl side chain containing bisphosphonate, caused an 80% reduction in parasitemia with no overt toxicity. Taken together, these results show that bisphosphonates appear to be useful lead compounds for the development of novel antiamebic and antimalarial drugs.

AB - The effects of a series of 102 bisphosphonates on the inhibition of growth of Entamoeba histolytica and Plasmodium falciparum in vitro have been determined, and selected compounds were further investigated for their in vivo activity. Forty-seven compounds tested were active (IC50 < 200 μM) versus E. histolytica growth in vitro. The most active compounds (IC 50 ∼ 4-9 μM) were nitrogen-containing bisphosphonates with relatively large aromatic side chains. Simple n-alkyl-1-hydroxy-1,1-bisphosphonates, known inhibitors of the enzyme farnesylpyrophosphate (FPP) synthase, were also active, with optimal activity being found with C9-C10 side chains. However, numerous other nitrogen-containing bisphosphonates known to be potent FPP synthase inhibitors, such as risedronate or pamidronate, had little or no activity. Several pyridine-derived bisphosphonates were quite active (IC50 ∼ 10-20 μM), and this activity was shown to correlate with the basicity of the aromatic group, with activity decreasing with increasing pKa values. The activities of all compounds were tested versus a human nasopharyngeal carcinoma (KB) cell line to enable an estimate of the therapeutic index (TI). Five bisphosphonates were selected and then screened for their ability to delay the development of amebic liver abscess formation in an E. histolytica infected hamster model. Two compounds were found to decrease liver abscess formation at 10 mg/kg ip with little or no effect on normal liver mass. With P. falciparum, 35 compounds had IC50 values <200 μM in an in vitro assay. The most active compounds were also simple n-alkyl-1-hydroxy-1,1-bisphosphonates, having IC50 values around 1 μM. Five compounds were again selected for in vivo investigation in a Plasmodium berghei ANKA BALB/c mouse suppressive test. The most active compound, a C9 n-alkyl side chain containing bisphosphonate, caused an 80% reduction in parasitemia with no overt toxicity. Taken together, these results show that bisphosphonates appear to be useful lead compounds for the development of novel antiamebic and antimalarial drugs.

UR - http://www.scopus.com/inward/record.url?scp=9144255536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144255536&partnerID=8YFLogxK

U2 - 10.1021/jm030084x

DO - 10.1021/jm030084x

M3 - Article

VL - 47

SP - 175

EP - 187

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 1

ER -